NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma

16-Jan-2012 - France

NovAliX SAS announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.

Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.

This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances